Welcome to our dedicated page for NYXOAH S A SEC filings (Ticker: NYXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nyxoah SA (NYXH) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, providing detailed information on its Genio hypoglossal neurostimulation system for obstructive sleep apnea (OSA), financing transactions and risk factors. On Stock Titan’s SEC filings page, you can review these documents alongside AI-powered summaries that help explain their content in plain language.
Nyxoah uses Form 6-K current reports to furnish press releases and transaction details to U.S. investors. Recent 6-K filings describe private placements and registered direct offerings of ordinary shares, a subscription agreement for amortizing senior unsecured convertible notes, and the intended use of proceeds to support U.S. and international commercialization of the Genio system, fund clinical research, and finance upgrades and cost reduction initiatives. Other 6-Ks attach quarterly financial reports, preliminary results, and disclosures about FDA approval of the Genio system for a defined subset of adult patients with moderate to severe OSA.
Filings also contain extensive risk factor discussions, including sections on intellectual property litigation risk, market acceptance of the Genio system, and regulatory pathways in the United States and abroad. Additional exhibits cover underwriting agreements, legal opinions related to securities offerings, and information incorporated by reference into Nyxoah’s shelf registration statements on Form F-3 and equity compensation registration statements on Form S-8.
On this page, AI-generated highlights can point out key elements in Nyxoah’s filings, such as financing terms, reported cash position, regulatory milestones, and legal proceedings, while links to the full EDGAR documents allow for deeper review. Investors can also monitor how new 6-K submissions update or supplement existing registration statements and risk disclosures over time.
Nyxoah announced U.S. FDA approval of its Genio system for a specific group of adult OSA patients with an Apnea-Hypopnea Index between 15 and 65. The Genio system remains the company’s only commercial product and its future performance depends on physician, payer and patient adoption in target markets.
The company provided preliminary, unaudited Q2 2025 results showing revenue of ~€1.3 million (a 73% increase versus Q2 2024), operating expenses of ~€20.7 million (a 50% increase) and cash, cash equivalents and financial assets of ~€43.0 million as of June 30, 2025. Management expects the ACCCESS clinical study to close enrollment before reaching all 106 potential patients; enrolled patients will be assessed at 12 months post-implant for co-primary endpoints (AHI and ODI) and followed for five years. The company also announced a reorganization to transition ongoing R&D activities to the United States and Belgium. The financial figures are preliminary and unaudited and may change after review.
Nyxoah SA (NASDAQ: NYXH) has submitted a Form 6-K to the U.S. Securities and Exchange Commission for the month of June 2025.
The filing’s sole purpose is to furnish – not file – a press release dated 27 June 2025, which is attached as Exhibit 99.1. No financial statements, earnings data, or transactional details are included in the body of the report. Consistent with Exchange Act rules, the furnished information is explicitly excluded from Section 18 liability and will not be incorporated by reference into other SEC filings unless specifically stated.
The document is signed by Chief Financial Officer John Landry on behalf of the company. Apart from procedural disclosures (paper-filing check boxes, form type election, and signature block), the 6-K contains no additional operational, strategic, or financial commentary. Investors must review Exhibit 99.1 directly to understand the substance of the press release.